SCHEMBL4715635

SCHEMBL4715635

O=c1ccc2c(ccn2Cc2c(Cl)cccc2Cl)n1-c1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.52
NPSR1 Q6W5P4 2/20 0.52
LMNA P02545 1/20 0.42
ALDH1A1 P00352 8/20 0.40
KDM4E B2RXH2 7/20 0.40
HPGD P15428 4/20 0.40
CYP3A4 P08684 2/20 0.40
MAPT P10636 2/20 0.40
CYP2C9 P11712 2/20 0.40
CYP2C19 P33261 2/20 0.40
CYP1A2 P05177 1/20 0.40
GAA P10253 1/20 0.38
MAPK1 P28482 1/20 0.38
P2RX7 Q99572 1/20 0.38
HTT P42858 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.37
PKM P14618 2/20 0.37
MAPK14 Q16539 1/20 0.36
MEN1 O00255 1/20 0.36
CRHBP P24387 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4713845 0.84 BRD4 (0.46) ALDH1A1KDM4EHPGDHTTSMN1; SMN2
SCHEMBL4714110 0.82 LMNA (0.44) POLBNPSR1LMNAALDH1A1KDM4E
SCHEMBL4715863 0.81 CYP3A4 (0.46) POLBALDH1A1KDM4EHPGDCYP3A4
SCHEMBL4716315 0.81 ALDH1A1 (0.47) POLBLMNAALDH1A1KDM4EMAPT
SCHEMBL4711879 0.80 MEN1 (0.41) LMNAMAPTCYP1A2P2RX7HTT
SCHEMBL5124227 0.78 SMN1; SMN2 (0.43) LMNAALDH1A1KDM4EHPGDMAPT
SCHEMBL4715873 0.78 TP53 (0.46) POLBLMNAALDH1A1KDM4EHPGD
SCHEMBL5113137 0.78 HTR6 (0.44) LMNAALDH1A1KDM4EHPGDCYP3A4
SCHEMBL4715699 0.78 SLC6A2 (0.34) LMNAMEN1KMT2AOPRM1BRD4
SCHEMBL4716165 0.78 PIK3CD (0.40) POLBLMNACYP3A4CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7456286-B2 Bicyclic heteroaromatic compounds as kinase inhibitors UCB PHARMA, S.A. (BE) 2008-11-25 US claimed
US-20060122212-A1 Bicyclic heteroaromatic compounds as kinase inhibitors CELLTECH R&D LIMITED (GB) 2006-06-08 US claimed
US-7456286-B2 Bicyclic heteroaromatic compounds as kinase inhibitors UCB PHARMA, S.A. (BE) 2008-11-25 US disclosed
EP-1549648-B1 BICYCLIC HETEROAROMATIC COMPOUNDS AS KINASE INHIBITORS UCB PHARMA SA (BE) 2008-11-12 EP disclosed
US-20060122212-A1 Bicyclic heteroaromatic compounds as kinase inhibitors CELLTECH R&D LIMITED (GB) 2006-06-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060122212-A1 Bicyclic heteroaromatic compounds as kinase inhibitors MAP2K2, MAP2K7, MAP2K3 POLB 964/4885NPSR1 3985/4885LMNA 4269/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.